Health
Lipoprotein(a): The Heart Risk You Were Born With
Some men do everything right and still have a heart attack in their fifties. For a slice of them, the reason was written into their DNA before they were born, and it never showed up on a standard cholesterol panel.
You know the story. A guy who trained four days a week, kept his weight in check, never smoked, had a clean cholesterol panel every year. Then at 54 he is in an ambulance. Everybody says the same thing: he did everything right.
Sometimes he did. There is a heart risk factor that is not on a standard panel, is set almost entirely by genes you inherited, and barely responds to anything you do in the gym or the kitchen. It is called lipoprotein(a), written Lp(a) and usually said out loud as "L-P-little-a." Roughly one in five people is walking around with a high level and has no idea. Here is the honest read on what it is, why you only need to test it once, and what to actually do with the result. This is education, not medical advice.
What Lp(a) actually is
Start with an LDL particle, the standard bad-cholesterol carrier. Now bolt an extra protein onto it called apolipoprotein(a). That combination is Lp(a). It behaves like LDL in the artery wall, and it brings some extra problems of its own, including inflammatory and clot-related properties tied to the oxidized phospholipids it carries (Kronenberg et al., 2022).
The part that matters for you is where your level comes from. The LPA gene contains a repeating stretch of DNA, and the number of copies you inherited largely sets how much Lp(a) your liver makes for the rest of your life (Schmidt et al., 2016). You did not earn your number and you cannot train it off. It was decided at conception, it is close to fixed by early adulthood, and it does not care how your last cut went.
How common it is, and how much it matters
High Lp(a) is not a rare genetic curiosity. Between 10 and 20 percent of the population has concentrations high enough to raise risk, which works out to more than a billion people worldwide. For the men at the high end, the effect is not subtle. High Lp(a) predicts roughly two to threefold increases in risk for heart attack, peripheral artery disease, and aortic valve stenosis (Kamstrup, 2021).
Aortic valve stenosis is the one that surprises people. Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve, meaning it does not just clog arteries, it stiffens the valve your heart pumps through (Kronenberg et al., 2022).
There is even a signal outside the usual atherosclerosis story. In the UK Biobank, across 435,579 people and 20,432 cases of new atrial fibrillation, each 50 nmol/L increase in Lp(a) came with about 3 percent higher risk of developing AF, and only about 39 percent of that risk appeared to run through artery disease (Mohammadi-Shemirani et al., 2022). The effects reach further than the plumbing.
This is causal, not just correlated
Plenty of blood markers travel alongside heart disease without causing it. Lp(a) is in a different category, and the reason is genetics.
Because your Lp(a) level is assigned by gene variants at birth, researchers can compare people who were effectively randomized by nature into high and low lifetime exposure. Do that across hundreds of thousands of people and the answer is consistent. A European Atherosclerosis Society consensus panel reviewing that body of work concluded the association between Lp(a) concentration and cardiovascular outcomes is causal and continuous, holds across different ethnic groups, and shows up even in people whose LDL cholesterol is very low (Kronenberg et al., 2022).
That last clause is the one to sit with. A perfect LDL number does not cancel a high Lp(a).
One useful thing the same panel ruled out: current evidence does not support Lp(a) as a risk factor for venous blood clots or impaired clot breakdown (Kronenberg et al., 2022). If you have read otherwise online, that claim has not held up.
Why you only need the test once
Your Lp(a) does not drift the way your triglycerides do after a bad month. It is stable, so a single measurement tells you what you have been living with and what you will keep living with. The European panel recommends testing Lp(a) at least once in adults, with cascade testing through the family when there is familial hypercholesterolaemia, a family history of very high Lp(a), or early heart disease in relatives (Kronenberg et al., 2022).
Once in a lifetime. It is one of the few tests in medicine where that is genuinely the recommendation. It is a standard blood draw, it can usually be added to a panel you are already getting, and there is no fasting ritual to plan around.
If your father or brother had a heart attack in his forties or fifties, this is the test to ask about. Not another repeat lipid panel.
The hard part: you cannot lower it in the usual ways
Here is where most articles get vague, so let me be blunt. Losing fat does not fix it. Cutting saturated fat does not fix it. Statins do not lower Lp(a), and depending on the drug they can nudge it slightly the wrong way. The levers that work for every other lipid marker do not work here.
There is also a math problem with partial lowering. A Mendelian randomization analysis pooling data on tens of thousands of coronary heart disease cases found that 10 mg/dL lower genetically predicted Lp(a) was associated with 5.8 percent lower risk. Compare that with LDL, where 10 mg/dL lower was associated with 14.5 percent lower risk. Run the numbers and it would take roughly a 100 mg/dL drop in Lp(a) to buy the same risk reduction as a 38.67 mg/dL drop in LDL (Burgess et al., 2018).
That single finding explains a decade of failed attempts. Older drugs that shaved 25 to 35 percent off Lp(a) were never going to move an outcome, because the absolute drop was too small to matter. It was not a flawed idea. It was an underpowered dose.
What you can actually do about it today
If your number comes back high, the play is not to attack Lp(a) directly. It is to take every other risk factor you can control and drive it into the ground, because your baseline risk started higher than the next guy's.
The European panel's guidance is exactly that: without specific Lp(a)-lowering therapy available, pursue early and intensive management of the other risk factors, scaled to your overall cardiovascular risk and how high your Lp(a) actually is (Kronenberg et al., 2022). In practice that means your LDL and apoB targets get stricter, your blood pressure gets taken seriously in your forties instead of your sixties, smoking is off the table entirely, and your training and body composition stop being about how you look.
For the extreme cases, very high Lp(a) with cardiovascular disease that keeps progressing despite everything else being optimized, lipoprotein apheresis is an option (Kronenberg et al., 2022). That is a specialist conversation, not a lifestyle tweak.
What is coming, and the honest caveat
This is the most active area in lipid medicine right now. New drugs that switch off Lp(a) production at the genetic level can cut levels by up to about 90 percent, which is finally the size of drop the math says you would need.
Three large phase 3 trials are running to find out whether that translates into fewer heart attacks: Lp(a)HORIZON testing pelacarsen, OCEAN(a) testing olpasiran, and ACCLAIM-Lp(a) testing lepodisiran (Mansoor et al., 2025).
Now the caveat, and it matters. As of that review, there were no published trials showing that lowering Lp(a) on top of good LDL control actually reduces cardiovascular events (Mansoor et al., 2025). Dropping a number is not the same as preventing a heart attack. We have been burned by that assumption before. The trials will tell us, and until they read out, nobody should be promising you anything.
When to talk to a doctor
Bring it up if a first-degree relative had a heart attack or stroke before 55 in men or 65 in women, if you have already had a cardiac event yourself, if you have been diagnosed with familial hypercholesterolaemia, or if your risk picture has never quite matched your clean-looking lab work. If you are already on a cholesterol medication, do not change anything based on a number you read about here.
The verdict
Lp(a) is the closest thing men's cardiovascular health has to a hand you were dealt. One in five people is holding a bad one, most of them do not know it, and no amount of clean eating changes the card.
What it does change is how hard you play everything else. Get it measured once. If it comes back high, that is not a sentence, it is information that should make you and your doctor more aggressive about the risk factors you can actually move. And keep an eye on those trials, because the answer to whether this becomes treatable is a few years out, not decades.
That is the verdict.
References
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022. https://pubmed.ncbi.nlm.nih.gov/36036785/
- Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021. https://pubmed.ncbi.nlm.nih.gov/33236085/
- Burgess S, Ference BA, Staley JR, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018. https://pubmed.ncbi.nlm.nih.gov/29926099/
- Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016. https://pubmed.ncbi.nlm.nih.gov/27074913/
- Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022. https://pubmed.ncbi.nlm.nih.gov/35450575/
- Mansoor T, Ismayl M, Parikh S, et al. Emerging pharmacological strategies in lipoprotein(a) reduction. Proc (Bayl Univ Med Cent). 2025. https://pubmed.ncbi.nlm.nih.gov/40821459/
Common questions
What is lipoprotein(a) and how is it different from LDL cholesterol?
Lp(a) is an LDL-like particle with an extra protein called apolipoprotein(a) attached to it. It behaves like LDL inside an artery wall but carries additional inflammatory properties, and it is associated with calcification of the aortic valve as well as artery disease (Kronenberg, 2022). The bigger difference is control. Your LDL responds to diet, body fat, and medication. Your Lp(a) level is largely set by the LPA gene you inherited and stays roughly fixed for life (Schmidt, 2016).
How common is high Lp(a)?
Between 10 and 20 percent of the population has a concentration high enough to raise cardiovascular risk, which is over a billion people worldwide. In that group, high Lp(a) predicts roughly two to threefold increases in risk of heart attack, peripheral artery disease, and aortic valve stenosis (Kamstrup, 2021). Most men who have it have never been tested and do not know.
Why do you only need to test Lp(a) once?
Because it is genetically determined and stays stable across your adult life, one measurement tells you what you have been carrying and what you will keep carrying. The European Atherosclerosis Society recommends testing at least once in adults, with cascade testing through the family when there is familial hypercholesterolaemia, a family history of very high Lp(a), or early heart disease in relatives (Kronenberg, 2022).
Can diet or exercise lower Lp(a)?
Not meaningfully. The levers that move LDL, triglycerides, and blood pressure do not move Lp(a), and statins do not lower it either. That does not make training and body composition pointless, since a high Lp(a) is a reason to manage every other risk factor harder. It just means you should not expect a clean diet to fix this particular number.
Are there drugs that lower Lp(a)?
There are drugs in late-stage testing that cut Lp(a) by up to about 90 percent, and three large phase 3 outcome trials are running: Lp(a)HORIZON with pelacarsen, OCEAN(a) with olpasiran, and ACCLAIM-Lp(a) with lepodisiran. As of a 2025 review, no published trial had yet shown that lowering Lp(a) on top of good LDL control reduces cardiovascular events (Mansoor, 2025). The size of the drop matters, because genetic data suggest it takes roughly a 100 mg/dL reduction in Lp(a) to match the benefit of a 38.67 mg/dL reduction in LDL (Burgess, 2018).
My Lp(a) came back high. What now?
Take it to your doctor and use it to sharpen everything else. Guidance from the European panel is early, intensive management of your other risk factors, scaled to your overall cardiovascular risk and how high the number is (Kronenberg, 2022). In practice that usually means stricter LDL and apoB targets, blood pressure treated seriously and early, no smoking, and consistent training. For very high levels with progressing disease despite optimal management, lipoprotein apheresis is a specialist option.
